Cat. No.: HY-B0199

Mycophenolate Mofetil

(Synonyms: RS 61443; TM-MMF)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation.

For research use only. We do not sell to patients.

Purity: 99.83%
CAS No.: 128794-94-5
Formula: C₂₃H₃₁NO₇
Molecular Weight:433.49

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Mycophenolate Mofetil Chemical Structure

CAS No.: 128794-94-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.05 μM Compound: Mycophenolate	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
B-cell	IC₅₀	3.2 μM Compound: MMF	Immunosuppressive activity in BALB/c mouse B cells assessed as reduction in LPS-induced cell proliferation Immunosuppressive activity in BALB/c mouse B cells assessed as reduction in LPS-induced cell proliferation	[PMID: 32323537]
BHK-21	CC₅₀	3.43 μM Compound: 63	cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
LLC-MK2	CC₅₀	3.01 μM Compound: 63	Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
Splenocyte	EC₅₀	0.48 μM Compound: Mycophenolate mofetil	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation incubated for 48 hrs by MTT assay Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation incubated for 48 hrs by MTT assay	[PMID: 36596229]
Splenocyte	IC₅₀	0.21 μg/mL Compound: Mycophenolate mofetilf	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse B-lymphocyte proliferation Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse B-lymphocyte proliferation	[PMID: 38441877]
Splenocyte	IC₅₀	0.5 μM Compound: Mycophenolate mofetil	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation incubated for 48 hrs by MTT assay Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33544615]
Splenocyte	IC₅₀	1 μM Compound: Mycophenolate mofetil	Immunosuppressive activity in mouse splenocyte assessed as reduction in LPS-induced mouse B-cell proliferation Immunosuppressive activity in mouse splenocyte assessed as reduction in LPS-induced mouse B-cell proliferation	[PMID: 38128907]

In Vitro

The inosine monophosphate dehydrogenase is an important enzyme in the de novo synthesis of guanosine nucleotides in T and B lymphocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 128794-94-5
Appearance Solid
Molecular Weight 433.49
Formula C₂₃H₃₁NO₇
Color White to off-white
SMILES

O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC
Synonyms

RS 61443; TM-MMF
Structure Classification
- Phenols
- Monophenols
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (13)

All Flow CytometryCell Imaging/StainingCell Proliferation/Viability AssayBio/Physico-chemical AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

J Control Release

Target-oriented delivery of self-assembled immunosuppressant cocktails prolongs allogeneic orthotopic liver transplant survival. [Abstract]

2020 Dec 10;328:237-250. PMID: 32866593
Cell Death Dis

HNF4α-HKDC1 axis orchestrates a metabolic rewiring to promote migration and metastasis in advanced gastric cancer. [Abstract]

2026 Mar 23;17(1):347. PMID: 41866549
J Transl Med

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer. [Abstract]

2024 Feb 3;22(1):133. PMID: 38310229
Hepatobiliary Surg Nutr

Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation. [Abstract]

2023 Dec 1;12(6):835-853. PMID: 38115918

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):835-853. [Abstract]

To investigate the effects of immunosuppressants on PBMCs, peripheral blood mononuclear cells from healthy volunteers were exposed to Mycophenolate Mofetil (15 µg/mL, 3 days).

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):835-853. [Abstract]

The cytolytic activity of NK cells on K562 and HL60 cells. NK cells sorted by MACS were exposed to TAC, CSA, Mycophenolate Mofetil (15 µg/mL, 3 days), EVE, SIR, and CS and cultured for 3 d as effector cells.
Cell Rep

HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells. [Abstract]

2026 Jun 2;45(6):117490. PMID: 42234559
J Ethnopharmacol

Immunosuppressive effect of Columbianadin on maturation, migration, allogenic T cell stimulation and phagocytosis capacity of TNF-α induced dendritic cells. [Abstract]

2022 Mar 1:285:114918. PMID: 34919989
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
J Cell Mol Med

Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. [Abstract]

2021 Apr;25(7):3511-3523. PMID: 33713546

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

The morphology of Mycophenolate Mofetil-LA@DSPE-PEG and Mycophenolate Mofetil-LA@PEG-PLA characterized by transmission electron microscopy (TEM).

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

The diameters and zeta potentials of Mycophenolate Mofetil-LA@DSPE-PEG and Mycophenolate Mofetil-LA@PEG-PLA characterized by Dynamic light scattering (DLS).

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

Cell viabilities of Huh7 cells, SUN‐449 cells, LM3 cells and Hep1‐6 cells treated with free Mycophenolate Mofetil, Mycophenolate Mofetil‐LA@DSPE‐PEG and Mycophenolate Mofetil‐LA@PEG‐PLA for 48 h.

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

Cell cycles determined by flow cytometry. Cells were treated with free Mycophenolate Mofetil (2 µg/mL) or Mycophenolate Mofetil-LA NPs (at 2 µg/mL Mycophenolate Mofetil-equivalent dose) for 48 h.

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

Colony Formation of Hep1-6 cells, SUN-449 cells and Huh7 cells. Hep1-6 cells, SUN-449 cells and Huh7 cells were treated with drugs at 0.5, 2 and 4 µg/mL (Mycophenolate Mofetil-equivalent concentration), respectively, for 96 h.

Mycophenolate Mofetil purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523. [Abstract]

Images of Hep1‐6 tumours after treatment with drugs at 20 mg/kg (Mycophenolate Mofetil‐equivalent concentration). Mice were orally administrated with free MMF (20 mg/kg) or intravenously injected with MMF‐LA NPs (at 20 mg/kg MMF‐equivalent dose) every other day for four times.
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
bioRxiv

2025 Sep 21.
Biomed Pharmacother

Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. [Abstract]

2019 Oct:118:109305. PMID: 31545264

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (230.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1M NaOH : 33.33 mg/mL (76.89 mM; ultrasonic and adjust pH to 12 with 1M NaOH)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3069 mL

11.5343 mL

23.0686 mL

5 mM

0.4614 mL

2.3069 mL

4.6137 mL

10 mM

0.2307 mL

1.1534 mL

2.3069 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17(2):75-92. [Content Brief]

[2]. Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278-298. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
1M NaOH / DMSO	1 mM	2.3069 mL	11.5343 mL	23.0686 mL	57.6715 mL
	5 mM	0.4614 mL	2.3069 mL	4.6137 mL	11.5343 mL
	10 mM	0.2307 mL	1.1534 mL	2.3069 mL	5.7671 mL
	15 mM	0.1538 mL	0.7690 mL	1.5379 mL	3.8448 mL
	20 mM	0.1153 mL	0.5767 mL	1.1534 mL	2.8836 mL
	25 mM	0.0923 mL	0.4614 mL	0.9227 mL	2.3069 mL
	30 mM	0.0769 mL	0.3845 mL	0.7690 mL	1.9224 mL
	40 mM	0.0577 mL	0.2884 mL	0.5767 mL	1.4418 mL
	50 mM	0.0461 mL	0.2307 mL	0.4614 mL	1.1534 mL
	60 mM	0.0384 mL	0.1922 mL	0.3845 mL	0.9612 mL
DMSO	80 mM	0.0288 mL	0.1442 mL	0.2884 mL	0.7209 mL
DMSO	100 mM	0.0231 mL	0.1153 mL	0.2307 mL	0.5767 mL

Keywords

Mycophenolate Mofetil

13 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mycophenolate Mofetil

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

NMPA-Approved Drug Library

Phenols Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Mycophenolate Mofetil

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mycophenolate Mofetil Related Classifications

HY-B0199 Related Classifications